Richard Barry, Director at Sarepta Therapeutics, Inc. (SRPT), bought 1,300 shares at $122.50 ($159K) on 2019-08-12, disclosed to the SEC on 2019-08-13.
Open-market purchase of $159k SRPT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Nothing distinguishes this filing.
| Filing → |
| SAVA | BUY | 2025-11-24 | $828K | — | Filing → |
| SAVA | BUY | 2025-11-20 | $404K | — | Filing → |
| SAVA | BUY | 2025-09-23 | $16K | — | Filing → |